The Effects of Rapamycin in the Progression of Renal Fibrosis

Transplantation Proceedings

Volumn 39, Issue 2, 2007, Pages 457-459

  Damiao M J ^a   Bertocchi, A P F ^a   Monteiro, R M M ^a   Goncalves G M ^a   Cenedeze, M A ^a   Feitoza, C Q ^a   Marques, G D ^a   Giannocco, G ^b   Mazzali, M ^c   Teixeira, V P A ^d   dos Reis, M A ^d   Pacheco Silva, A ^a   Camara N O S ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; MESSENGER RNA; OSTEOGENIC PROTEIN 1; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; C57BL 6 MOUSE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; HISTOLOGY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FIBROSIS; LYMPHOCYTE PROLIFERATION; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; URETER OBSTRUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CREATININE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MICE; MICE, INBRED C57BL; RNA, MESSENGER; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33947128718     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.01.031     Document Type: Article

References (13)

1. Wolfe R.A., Ashby V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341 (1999) 1725
2. Hariharan S., Johnson C.P., Bresnahan B.A., et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342 (2000) 605
3. Halloran P.F., Melk A., and Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 10 (1999) 167
4. Zeisberg M., Hanai J., Sugimoto H., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 97 (2003) 964
5. Yang J., Dai C., and Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 161 (2005) 68
6. Okada H., and Kalluri R. Recapitulation of kidney development paradigms by BMP-7 reverses chronic renal injury. Clin Exp Nephrol 92 (2005) 100
7. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 35213 (2005) 1317
8. Lee V.W., and Chapman J.R. Sirolimus: its role in nephrology. Nephrology (Carlton) 106 (2005) 606
9. Morales J.M. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Kidney Int 99 suppl (2005) S124
10. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2011 (2005) 2517
11. Shihab F.S., Bennett W.M., Yi H., et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 654 (2004) 1262
12. Song K., Wang H., Krebs T.L., et al. Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J 251 (2006) 58
13. van der Poel H.G., Hanrahan C., Zhong H., et al. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 306 (2003) 380